Arcus Biosciences Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cancer treatment
The company specializes in creating a diverse portfolio of drug candidates that target various pathways involved in the immune response and tumor microenvironment, aiming to unlock the potential of the immune system in combating different types of cancers. Through its rigorous research and development efforts, Arcus strives to bring forth effective treatment options for patients and address significant unmet medical needs in oncology.
Gilead Sciences and Arcus Biosciences report sustained efficacy and safety in the Phase 2 EDGE-Gastric study for upper GI cancers, showing improved progression-free survival and objective response rates. New data from the ARC-9 study highlights significant survival benefits in metastatic colorectal cancer.
Companies Reporting Before The Bell • Gatos Silver (NYSEGATO) is estimated to report quarterly earnings at $0.09 per share on revenue of $83.00 million.
Arcus Biosciences sees a 17.1% surge as Gilead Sciences amends collaboration, investing $320M at $21.00/share. Accelerate joint programs in cancer therapy.
